Combination of vorinostat and flavopiridol is selectively cytotoxic to multidrug-resistant neuroblastoma cell lines with mutant TP53

As p53 loss of function (LOF) confers high-level drug resistance in neuroblastoma, p53-independent therapies might have superior activity in recurrent neuroblastoma. We tested the activity of vorinostat, a histone deacetylase inhibitor, and flavopiridol, a pan-Cdk inhibitor, in a panel of multidrug-...

Full description

Saved in:
Bibliographic Details
Published in:Molecular cancer therapeutics 2010-12, Vol.9 (12), p.3289-3301
Main Authors: Huang, Jen-Ming, Sheard, Michael A, Ji, Lingyun, Sposto, Richard, Keshelava, Nino
Format: Article
Language:English
Subjects:
Biomarkers, Tumor - metabolism
Cell Death - drug effects
Cell Line, Tumor
Drug Resistance, Multiple - drug effects
Drug Resistance, Neoplasm - drug effects
Drug Synergism
Flavonoids - chemistry
Flavonoids - pharmacology
Flavonoids - therapeutic use
G2 Phase - drug effects
Histone Deacetylase Inhibitors - pharmacology
Humans
Hydroxamic Acids - chemistry
Hydroxamic Acids - pharmacology
Hydroxamic Acids - therapeutic use
Mitosis - drug effects
Mutant Proteins - metabolism
Mutation - genetics
Neuroblastoma - drug therapy
Neuroblastoma - pathology
Piperidines - chemistry
Piperidines - pharmacology
Piperidines - therapeutic use
Protein Kinase Inhibitors - pharmacology
Tumor Suppressor Protein p53 - genetics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:As p53 loss of function (LOF) confers high-level drug resistance in neuroblastoma, p53-independent therapies might have superior activity in recurrent neuroblastoma. We tested the activity of vorinostat, a histone deacetylase inhibitor, and flavopiridol, a pan-Cdk inhibitor, in a panel of multidrug-resistant neuroblastoma cell lines that included lines with wild-type (wt) and transcriptionally active TP53 (n = 3), mutated (mt), and LOF TP53 (n = 4) or p14(ARF) deletion (n = 1). The combination of vorinostat and flavopiridol was synergistic and significantly more cytotoxic (P < 0.001) in cell lines with p53-LOF and in the clones stably transfected with dominant-negative p53 plasmids. Cell cycle analysis by flow cytometry showed prominent cell-cycle arrest in G(2)/M (37%) for a cell line with wt TP53 (SK-N-RA) at 16 to 20 hours, while cells with mt TP53 (CHLA-90) slipped into sub-G(1) at 6 to 24 hours (25%-40% specific cell death). The morphological hallmarks of mitotic cell death, including defective spindle formation and abnormal cytokinesis, were detected by confocal microscopy after the treatment with vorinostat + flavopiridol combination in CHLA-90. The combination caused reduction in the expression of G(2)/M proteins (cyclin B1, Mad2, MPM2) in 2 cell lines with mt TP53 but not in those with wt TP53. Plk1 expression was reduced in all treated lines. Small interfering RNA knockdown of Mad2 and cyclin B1 or Plk1 synergistically reduced the clonogenicity of CHLA-90 cells. The combination of HDAC inhibitor and flavopiridol may be a unique approach to treating neuroblastomas with p53 LOF, one that evokes induction of mitotic failure.
ISSN:1535-7163
1538-8514
1538-8514
DOI:10.1158/1535-7163.MCT-10-0562